Clinical Trials Logo

Ganglioglioma clinical trials

View clinical trials related to Ganglioglioma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03970785 Completed - Clinical trials for Surgical Procedure, Unspecified

Intraoperative Fluorescence of Ganglogliomas and Neuroepithelial Dysembryoplastic Tumors

FLUOGOD
Start date: July 15, 2018
Phase:
Study type: Observational

One of the key issues of tumour brain surgeries is to clearly define the borders of the tumor. The investigators proposed to evaluate the feasibility of intraoperative fluorescein guidance. Patients will be identified from the list of patients operated on under fluorescence to collect clinical datas. Surgical videos will be analyzed to assess the presence of intraoperative fluorescence and its subjectively judged intensity. MRI data will be extracted from the radiological reports to assess quality extraction. No additional data will be produced

NCT ID: NCT03900689 Completed - Glioma Clinical Trials

Social Determinants of Health in Glioblastoma Population

Start date: May 22, 2019
Phase:
Study type: Observational

The overall aim of this study is to prospectively characterize social health disparities in a cross-sectional cohort of glioma patients with attention to exploring and thematically categorizing the patient-specific and community-level factors. This will be conducted in two parts.

NCT ID: NCT02684058 Completed - Glioblastoma Clinical Trials

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Start date: December 28, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study was to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma (LGG) or relapsed or refractory high grade glioma (HGG)

NCT ID: NCT01999270 Completed - Glioma Clinical Trials

Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors

Start date: April 2013
Phase: Phase 1
Study type: Interventional

To determine if FDOPA-PET/MRI imaging can predict response to treatment of bevacizumab.